E
EGBOT
Guest
Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction
Source: Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction
HTML:
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program.
Source: Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction